They applied 0.625% glutaraldehyde solution to the defective edge for 2 min, and found that this reinforced the residual tissue edges and reduced the resected area. Glutaraldehyde solution has widely been used as a disinfectant and for fixation of specimens. It cannot be applied directly in humans because of its strong toxicity. In the field of cardiovascular surgery, the application of glutaraldehyde has been limited to preservation or stabilization of heart valve tissue and the autologous or xenologous pericardium. These tissues should be rinsed adequately before use in patients to eliminate any residual toxic agent. In 1988, Carpentier's group confirmed improvement of goat pericardium quality with preservation of the natural structure after 10 min of treatment with glutaraldehyde solution. Glutaraldehyde was next applied in the setting of acute aortic dissection to stabilize the fragile dissected aortic wall. These reports led to the widespread use of biological adhesives, including bovine serum albumin and glutaraldehyde, since 1998. Therefore, the clinical concept of stabilizing the fragile infected mitral leaflet proposed by Nakamura and colleagues report an analysis of their experience with a total of 35 patients undergoing isolated MV surgery for active IE between January 2004 and August 2015. They aggressively performed valve repair and preserved the valve in 86% of cases. In 30 patients undergoing MV repair, the in-hospital mortality rate was 3.3% and the 5-year survival rate was 89 ± 6%. Postoperative MV replacement was required in only 1 patient 2 months later, and no recurrence of endocarditis occurred in any of the cases. As described before, their results are not surprising in the modern era, but their innovative technique is noteworthy.

The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.

Received August 17, 2018; accepted August 22, 2018; released online September 1, 2018

Department of Cardiovascular Surgery, The Cardiovascular Institute, Tokyo, Japan

The opinions expressed in this article are not necessarily those of the editors or of the Japanese Circulation Society.
Nakamura and colleagues may be justified.

Although their study was approved by the local ethics committee, the major drawback is the lack of scientific background for clinical application of glutaraldehyde solution to the MV. This may be the first report describing the application of glutaraldehyde to the MV in consecutive patients with acute IE (although there is a report of a case operated in 2017). Thus, the optimal concentration and duration for application should be determined experimentally before clinical use. Their rationale was a report by Gorman et al indicating inactivation of common microorganisms by 0.2–2% solution within 2 min, which seems both reasonable and safe. The second drawback is that this was not a comparative study but a retrospective study of their technical modifications for consecutive patients without a control group. It is not possible to determine whether their results could be reproduced without the use of glutaraldehyde or with other disinfectants (e.g., povidone iodine) because the other operative techniques used were conventional. Therefore, although the retrospective nature of the study precluded discussion about whether use of glutaraldehyde is superior to other methods, it is reasonable to conclude that its use is safe without adverse events. The third drawback is the lack of long-term follow-up data. The mean follow-up period for their patients was only 4.3 ± 3.7 years. However, deterioration of glutaraldehyde-treated autologous pericardium is known to become evident from 10 years after surgery (Figure 2). The actual role of topical application of glutaraldehyde to the fragile mitral leaflet should be confirmed in further studies in larger cohorts with longer follow-up.

Nonetheless, these authors are to be congratulated on their innovative technique with excellent results in this critical setting. It should be emphasized that they experienced no reoperation beyond 2 months and no recurrence of IE over a mean follow-up period of 4.3 ± 3.7 years. This may have been due to the bactericidal effects of glutaraldehyde in addition to the formation of irreversible cross-linkages between collagen molecules. Interestingly, the beneficial effect of MV repair for IE was not apparent in a low-volume center. This simple but innovative technical modification may result in the more widespread adoption of MV repair for active IE, making the procedure reproducible and more durable at the general community level after careful inspection of its validity.

Disclosures
The author declares no conflicts of interest.

References


